Fact Source: Financial Supervisory Service DART / 2026-03-31
Disclosure Type: Decision on Acquisition of Shares and Investment Certificates of Other Corporations (Voluntary Disclosure) (Amended)
💡 3-Second Summary
Samsung Biologics’ U.S. subsidiary has updated its regulatory filing to finalize the acquisition date (March 31, 2026) and the total consideration (approximately KRW 521.5B) for purchasing a 100% stake in Human Genome Sciences from GSK.
📊 1. [Key Disclosure Content & Major Figures Summary]
- Reason for Amendment: Finalization of the scheduled acquisition date and the definitive consideration.
- Acquiring Entity: Samsung Biologics America, Inc. (A 100% owned subsidiary of Samsung Biologics).
- Target Company (Issuer): Human Genome Sciences, Inc. (Nationality: United States, Primary Business: Pharmaceutical Manufacturing).
- Acquisition Details & Figures Amendment:
- Number of Shares acquired & Ownership: 800 shares (100% ownership).
- Final Acquisition Value: (Pre-amendment) KRW 413,616,000,000 ➔ (Post-amendment) KRW 521,552,263,617 (Increased by KRW 107,936,263,617).
- Ratio to Total Assets of Controlling Entity: (Pre-amendment) 2.39% ➔ (Post-amendment) 3.01% (Compared to Samsung Biologics’ consolidated total assets of KRW 17,336,296,349,511 at the end of FY2024).
- Scheduled Acquisition Date: (Pre-amendment) Undetermined ➔ (Post-amendment) 2026-03-31.
- Financial Composition & Acquisition Terms:
- The total finalized consideration stands at USD 353,068,144.88, translated using the initial FX rate of 1,477.20 KRW/USD from the initial reference date (December 19, 2025).
- Within the total payment, USD 73,068,144.88 represents the consideration for transferring manufacturing inventories and raw materials held by the issuer. The net valuation for facilities and equity alone stands at USD 280,000,000.
- Purpose of Acquisition: To secure a U.S. local manufacturing facility to address long-term local demand in the United States.
📈 2. [Expert Insight: What This Disclosure Means for Investors]
This regulatory amendment signifies that the scheduled acquisition date and the definitive price for the previously announced U.S. biomanufacturing facility acquisition have been updated and finalized as of March 31, 2026. The definitive acquisition price increased by approximately KRW 107.9B to a total of KRW 521.5B compared to the initial report. According to the text, this adjustment reflects the inclusion of costs associated with taking over raw materials and production inventories valued at USD 73.07M.
From a corporate finance perspective, this transaction represents an equity asset acquisition equivalent to 3.01% of the parent company’s consolidated asset base. Because the target entity (Human Genome Sciences, Inc.) is exempt from external auditing mandates, historical metrics such as localized revenue or net margin details are omitted from this filing. Consequently, the future financial impact cannot be determined from this filing alone. Market participants could evaluate the long-term operational efficiency of this site relative to the stated goal of supporting regional U.S. demand via subsequent disclosures and financial reports.
📝 Editor’s Comment (by K-STOCK Editor)
The scheduled acquisition date for the U.S. manufacturing facility acquisition transaction initially publicized in December 2025 has been adjusted to March 31, 2026. The purchase consideration was revised upward by roughly KRW 107.9B compared to the preliminary estimate, which reflects the finalized payment for transferring ongoing manufacturing materials and operational inventories. While the 100% equity parameters are now set, the filing omits financial baseline matrices (assets, liabilities, revenue) for the acquired entity due to its non-audited status. As the exact baseline profitability of the facilities remains unstated, global market participants may avoid assuming immediate closing conclusions based on this filing alone and should monitor subsequent disclosures and official financial statements to verify the actual implementation status.
📢 Disclaimer & Source Information
Source: This content was structured and newly generated based on official data submitted to the Financial Supervisory Service electronic disclosure system (DART).
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
